A Clinical Trial to Evaluate the Efficacy of ConcenTrace to Buffer pH Levels Within the Body.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06122597

Enrollment

Registered

2023-11-08

Start date

2023-10-05

Completion date

2024-01-31

Last updated

2024-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brief summary

This virtual single-arm trial will last 12 weeks. Participants will take the drops daily and complete questionnaires at Baseline, Week 4, Week 8, and Week 12. Urine pH measurements will be taken at Baseline, Week 4, Week 8, and Week 12 using pH test strips.

Interventions

OTHERConcenTrace

The product contains concentrated seawater from Utah's inland sea.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Male or female. Aged 18+. Generally healthy - don't live with any uncontrolled disease. Willing to maintain their standard dietary pattern, activity level, and body weight for the duration of the study.

Exclusion criteria

* Anyone with a pre-existing chronic condition that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. Anyone with known severe allergic reactions. Women who are pregnant, breastfeeding, or attempting to become pregnant. Anyone unwilling to follow the study protocol.

Design outcomes

Primary

Measure	Time frame	Description
Changes in urine pH levels. [Timeframe: Baseline to Week 12]	12 weeks	Participants will use pH test strips to measure urine pH. Changes in urine pH will be evaluated.

Secondary

Measure	Time frame	Description
Change in score on the Metabolic Screening Questionnaire.	12 weeks	A Metabolic Screening Questionnaire (MSQ) was developed by the Toronto Centre for Naturopathic Medicine. The symptoms represented on a MSQ represent symptoms commonly associated with inflammation and toxicity. Participants will rate frequency and intensity of applicable symptoms according to the following scores: * Absent or rare symptoms - 0 points * Occasional, mild symptoms - 1 point * Occasional, severe symptoms - 2 points * Frequent, mild symptoms - 3 points * Frequent, severe symptoms - 4 points

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026